Risk of Development Stagnation Due to Termination or Amendment of Outsourced R&D Contracts
First written in FY2017. 4 of 5 entries say "Restated". Latest entry: FY2026.
4 other companies' latest entry also says "Restated".
- FY2026RestatedAnnual report
「If these agreements are amended on terms unfavorable to us, or if they are terminated upon expiration, cancellation or for any other reason, this may hinder the advancement of our R&D activities and affect our financial position and results of operations.」
The risk of development delays due to the termination or amendment of outsourcing agreements for compound optimization, drug substance manufacturing, CRO services and other activities remains. - FY2022RestatedAnnual report
「If these agreements are amended on terms unfavorable to us, or if they are terminated upon expiration, cancellation or for any other reason, this may hinder the advancement of our R&D activities and affect our financial position and results of operations.」
The risk of development delays due to the termination or amendment of outsourcing agreements for compound optimization, drug substance manufacturing, CRO services and other activities remains. - FY2021RestatedAnnual report
「If these agreements are amended on terms unfavorable to us, or if they are terminated upon expiration, cancellation or for any other reason, this may hinder the advancement of our R&D activities and affect our financial position and results of operations.」
The risk of development delays due to the termination or amendment of outsourcing agreements for compound optimization, drug substance manufacturing, CRO services and other activities remains. - FY2020RestatedAnnual report
「If these agreements are amended on terms unfavorable to us, or if they are terminated upon expiration, cancellation or for any other reason, this may hinder the advancement of our R&D activities and affect our financial position and results of operations.」
The risk of development delays due to the termination or amendment of outsourcing agreements for compound optimization, drug substance manufacturing, CRO services and other activities remains. - FY2017First statedAnnual report
「If these agreements are amended on terms unfavorable to us, or if they are terminated upon expiration, cancellation or for any other reason, this may hinder the advancement of our R&D activities and affect our financial position and results of operations.」
Discloses the risk that termination or unfavorable amendments to outsourcing agreements for compound optimization, drug substance manufacturing, CRO services and other activities could hinder R&D, given the company’s reliance on external contractors.